Kura Oncology, Inc. (KURA) Institutional Ownership

Ownership Summary

Kura Oncology, Inc. (NASDAQ:KURA) currently has 199 active institutional owners and shareholders as of today (September 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• The collective stake of institutional investors in Kura Oncology moved to 96.7% in September 2025, a shift up from the 94.5% reported for June 2025.
• The company experienced a 4.80% quarterly change in institutional shares held, alongside an increase of 11.80% in total owners annually.
• A review of institutional activity for Kura Oncology shows 113 of 199 filers increasing their positions, while 56 reduced their stake, and 30 remained unchanged.
• This class of investors increased its holdings in Kura Oncology to 83.94Mn shares for the 13F-cycle ending September 2025, up by 3.84Mn shares quarter on quarter, and up 1.76Mn shares year over year.
• With 9.52Mn shares, BlackRock, Inc. commands the largest institutional position in Kura Oncology as of September 30, 2025, equating to 10.96% of the company.
• Among the most significant buyers of Kura Oncology during September 2025 were GOLDMAN SACHS GROUP INC (1.68Mn), AQR CAPITAL MANAGEMENT LLC (1.30Mn), JACOBS LEVY EQUITY MANAGEMENT, INC (1.12Mn), BVF INC/IL (863.03K), Pale Fire Capital SE (587.69K).
• Leading sellers of Kura Oncology stock in September 2025 included EcoR1 Capital, LLC (3.33Mn), ARMISTICE CAPITAL, LLC (1.53Mn), JANUS HENDERSON GROUP PLC (561.91K), MILLENNIUM MANAGEMENT LLC (527.82K), Prosight Management, LP (422.67K).
• The top 10 institutional holders of Kura Oncology for the quarter ending September 2025 included BlackRock, Inc. (9.52Mn), BVF INC/IL (8.62Mn), SUVRETTA CAPITAL MANAGEMENT, LLC (8.12Mn), VANGUARD GROUP INC (5.47Mn), ARMISTICE CAPITAL, LLC (4.67Mn), STATE STREET CORP (3.34Mn), Prosight Management, LP (2.76Mn), GOLDMAN SACHS GROUP INC (2.61Mn), AQR CAPITAL MANAGEMENT LLC (2.24Mn), JACOBS LEVY EQUITY MANAGEMENT, INC (2.22Mn).